Communiqués AbbVie Inc. Thailand S.E.

Actions

ABBV19

TH8483124005

Produits pharmaceutiques

Cours en clôture Thailand S.E. 18/08/2026			Varia. 5j.	Varia. 1 janv.
8,250 ^THB	+0,61%		+1,23%	+13,01%

17/08	États-Unis : record d'émissions obligataires " Investment Grade » en août, portées par les investissements dans l'IA	MT
17/08	AbbVie Inc. : Wells Fargo Securities toujours à l'achat	ZM

Communiqués

14:03	AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support	PR
11/08	Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices	PR
05/08	UBRELVY(R) (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
04/08	Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence	PR
04/08	UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment	AQ
31/07	AbbVie: Q2 Earnings Snapshot	AQ
31/07	AbbVie Reports Second-Quarter 2026 Financial Results	PR
30/07	AbbVie Announces European Commission Approval of RINVOQ for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo	AQ
30/07	AbbVie Announces European Commission Approval of RINVOQ for the Treatment of Adults and Adolescents with Severe Alopecia Areata	AQ
30/07	JUVÉDERM® Day Returns to U.S. on August 19	PR
29/07	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo	PR
29/07	AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata	PR
23/07	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	BU
17/07	Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients	PR
14/07	SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development	PR
07/07	AbbVie Announces TEPKINLY(R) (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	AQ
06/07	AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	PR
29/06	AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	PR
29/06	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata	PR
29/06	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo	PR
26/06	SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	PR
26/06	AbbVie to Host Second-Quarter 2026 Earnings Conference Call	PR
24/06	BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026	PR
23/06	Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients	PR
23/06	AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection	PR